With this method, you draw liquid CBD oil held in a cartridge past a heating element that atomizes the CBD — producing a vapor that you inhale.
In short, pharmacokinetics refers to the sum of your body’s mechanisms for absorption and elimination, the characteristics of CBD itself, and numerous external factors that can either help or hinder the way you assimilate and use CBD.
Additionally, the route of entry, or delivery method, has a lot to do with how much and how quickly CBD enters the bloodstream.
By contrast, the mean residence time for injected CBD, in the same study, was 3.3 hours .
Additionally, digestive acids and enzymes destroy a large percentage of CBD before it has a chance to be absorbed. And the small amount that gets through the intestinal wall is subject to being metabolized by the liver before it reaches the rest of the body.
In one experiment, cookies infused with 40 mg of CBD produced peak blood CBD levels between 1.5 and 3 hours after ingestion .
A more elaborate and less irritating inhalation form similar to smoking is vaping — which is done with a vaporizer pen.
Here is a guide for our Good Remedy CBD products:
In practice, taking CBD oil means we are required to listen our bodies, carefully observing any effects we experience, both positive or negative.
If you were expecting us to tell you exactly how much CBD to take, this may not be answer you were hoping for. But this really is an opportunity to create a better dialogue with your body, giving it just the right amount of CBD it needs.
1 capsule or gummie contains 10mg CBD
Upon swallowing, CBD passes through the digestive system, after which it enters the hepatic portal where much of it is broken down by liver enzymes. What’s left then enters the bloodstream. This is known as the ‘first-pass effect.’
Even if you’re using the up titration method, it’s still a good idea to know roughly how much CBD you are taking by working out how many milligrams of CBD are in each drop, capsule or inhalation.
What we’re talking here is a personalised approach, and definitely not the one-size-fits-all dosage regime we’re currently used to.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
3x increase in Cmax) and a faster onset/absorption (
The study included a subjective survey comprising eight questions to aid in the understanding of CUREfilm® OTF as an acceptable dosage form. Results showed that none of the participants felt discomfort, pain, numbness or irritation during administration. 80% indicated “great” palatability, with 90% rating the CUREfilm® OTF experience as very pleasant or neutral.
Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology
CURE’s clinical pipeline includes CUREfilm®Blue (sildenafil to treat erectile dysfunction), and CUREfilm®Canna (THC and CBD). Other OTC wellness products include Vitamin D, BCP Sleep, and Electrolytes. (Visit CURE’s catalog for the complete list.) As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
OXNARD, Calif., July 15, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film (OTF) showed improved bioavailability of cannabidiol in healthy subjects, compared with 25mg soft gels. Specifically, a pharmacokinetic (PK) study in 14 healthy adults showed a significantly higher serum concentration (Cmax) and significantly faster absorption (Tmax) from CURE’s CBD OTF dose form than from a commercially available CBD soft gel. The study also suggests that the CUREform™ delivery platform, which entails solubilization and encapsulation of the molecule, might deliver better results than solubilization alone, as used in the soft gel product, and may play a synergistic or additive role in bioavailability.
3x decrease in Tmax), compared to the reference product. No safety concerns were reported. In both arms of the study, the product was administered orally (PO) and, hence, ingested.
About the Study
This open-label, randomized, single-dose, crossover study of 14 healthy adults compared the pharmacokinetics of a commercially available soft gel formulation (liquid encapsulated within a shell) of 25mg CBD to 25mg of CBD delivered via CUREfilm®, CURE’s oral thin film, or OTF, dose form. CUREfilm® OTF resulted in a significantly higher maximum serum concentration (